• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Eur Heart J Cardiovasc Imaging . Prognostic value of right ventricular dilatation in patients with COVID-19: a multicentre study

tetano

Editor, Senior Moderator
Eur Heart J Cardiovasc Imaging


. 2021 May 19;jeab067.
doi: 10.1093/ehjci/jeab067. Online ahead of print.
Prognostic value of right ventricular dilatation in patients with COVID-19: a multicentre study


Laurie Soulat-Dufour[SUP] 1 [/SUP], Charles Fauvel[SUP] 2 [/SUP], Orianne Weizman[SUP] 3 4 [/SUP], Thomas Barbe[SUP] 2 [/SUP], Th?o Pezel[SUP] 5 [/SUP], Delphine Mika[SUP] 6 [/SUP], Joffrey Cellier[SUP] 7 [/SUP], Laura Geneste[SUP] 8 [/SUP], Vassili Panagides[SUP] 9 [/SUP], Wassima Marsou[SUP] 10 [/SUP], Antoine Deney[SUP] 11 [/SUP], Sabir Attou[SUP] 12 [/SUP], Thomas Delmotte[SUP] 13 [/SUP], Sophie Ribeyrolles[SUP] 14 [/SUP], Pascale Chemaly[SUP] 15 [/SUP], Clement Karsenty[SUP] 16 [/SUP], Gauthier Giordano[SUP] 3 [/SUP], Alexandre Gautier[SUP] 15 [/SUP], Baptiste Duceau[SUP] 4 [/SUP], Willy Sutter[SUP] 4 [/SUP], Corentin Chaumont[SUP] 2 [/SUP], Pierre Guilleminot[SUP] 17 [/SUP], Audrey Sagnard[SUP] 17 [/SUP], Julie Pastier[SUP] 16 [/SUP], Antonin Trimaille[SUP] 18 [/SUP], Guillaume Bonnet[SUP] 4 7 [/SUP], Marjorie Canu[SUP] 19 [/SUP], Augustin Coisne[SUP] 20 [/SUP], Ariel Cohen[SUP] 1 [/SUP]



Affiliations

Abstract

Aims: Although cardiac involvement has prognostic significance in coronavirus disease 2019 (COVID-19) and is associated with severe forms, few studies have explored the prognostic role of transthoracic echocardiography (TTE). We investigated the link between TTE parameters and prognosis in COVID-19.
Methods and results: Consecutive patients with COVID-19 admitted to 24 French hospitals were retrospectively included. Comprehensive data, including clinical and biological parameters, were recorded at admission. Focused TTE was performed during hospitalization, according to clinical indication. Patients were followed for a primary composite outcome of death or transfer to intensive care unit (ICU) during hospitalization. Among 2878 patients, 445 (15%) underwent TTE. Most of these had cardiovascular risk factors, a history of cardiovascular disease, and were on cardiovascular treatments. Dilatation and dysfunction were observed in, respectively, 12% (48/412) and 23% (102/442) of patients for the left ventricle, and in 12% (47/407) and 16% (65/402) for the right ventricle (RV). Primary composite outcome occurred in 44% (n = 196) of patients [9% (n = 42) for death without ICU transfer and 35% (n = 154) for admission to ICU]. RV dilatation was the only TTE parameter associated with the primary outcome. After adjustment, male sex [hazard ratio (HR) 1.56, 95% confidence interval (CI) 1.09 - 2.25; P = 0.02], higher body mass index (HR 1.10, 95% CI 1.02 - 1.18; P = 0.01), anticoagulation (HR 0.53, 95% CI 0.33 - 0.86; P = 0.01), and RV dilatation (HR 1.66, 95% CI 1.05 - 2.64; P = 0.03) remained independently associated with the primary outcome.
Conclusion: Echocardiographic evaluation of RV dilatation could be useful for assessing risk of severe COVID-19 developing in hospitalized patients.

Keywords: COVID-19; echocardiography; prognosis; right ventricular.
 
Back
Top Bottom